RPRX
ROYALTY PHARMA PLC
Lịch Sử Giá trị Nội Tại và Giá Thị trường trong Quá khứ.
-
Trading Information
-
Previous Close Price
$ 32,26
-
52-Week Range
$ 24,05 - $ 34,20
-
Market Cap
$ 18,60 B
-
Volume/Avg
21.25 / 4.25
-
Earnings Date
07/05
-
RSI
$ 53,16
-
-
Key Statistics
-
Fair Value
$ 47,00
-
Fair Value Percent
-31.36 %
-
Target Buy
$ 28,20
-
Industry
Biotechnology
-
Return on Equity
13.03%
-
Net Margin
37.95%
-
Capital Allocation
Exemplary
-
Economic Moat
Narrow
-
Long Term
Neutral
-
Profitable
Profitable
-
Risk And Uncertainty
Medium
-
Financial Health
Good
-
Rating
8
Definitions
-
-
Company Profile
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.